🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jesús García-Donás

ORCID: 0000-0001-7731-3601

Also affiliated with Hospital Universitario HM Sanchinarro

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial”.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00757-9

N/A

4.9DataRank · unranked

188 citations

Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu +90 more

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0103

N/A

1.8DataRank · unranked

76 citations

Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S. Chiu +134 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

Prognostic gene expression signature for high-grade serous ovarian cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.05.019

N/A

0.718DataRank · unranked

119 citations

S. Chen, Blake Gilks, C. Wang, S.C.Y. Leung, V. Chow +387 more

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Nature Medicine(2024)10.1038/s41591-024-02934-7

N/A

0.637DataRank · unranked

69 citations

Silvia Damian, Muhammad Furqan, Jesús García-Donás, Hiroo Imai, Antoîne Italiano +10 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin(2021)10.1007/s00428-021-03232-0

N/A

0DataRank · unranked

23 citations

Joshua Millstein, Gordana Popović, Nicola S. Meagher, Adelyn Bolithon, Aline Talhouk +95 more